Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2020-08-05 Director's Dealing
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-08-05 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2020, reporting the results of the 2020 Annual Meeting of Stockholders of Menlo Therapeutics Inc. It details the voting outcomes on three proposals, including election of directors, appointment of auditors, and approval of a reverse stock split amendment. The content focuses on the submission of matters to a vote of security holders and the official voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report, earnings release, or proxy statement, but specifically the official voting results from the annual meeting. The length and detail confirm it is not merely an announcement of a report but the actual voting results filing. Therefore, the correct classification is DVA with high confidence.
2020-08-03 English
SCHEDULE 14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes language urging stockholders to vote on proposals for the Annual Meeting, including election of directors, ratification of auditors, and approval of a reverse stock split amendment. The document is titled 'Definitive Additional Materials' related to the proxy statement and contains voting instructions and recommendations from the Board of Directors. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is 3420 characters, which is consistent with a proxy solicitation document rather than a full annual report or other filings. Therefore, the correct classification is PSI with high confidence.
2020-07-14 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-02 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-02 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.